DexCom Inc at Canaccord Genuity Growth Conference Transcript

Edited Transcript of DXCM.OQ presentation 7-Aug-19 6:00pm GMT

...Great. So we're going to continue on with the MedTech team here. I want to thank everybody for joining us again. This is 39th installment of Canaccord's Global Growth Conference. I appreciate everyone's participation. I'm Kyle Rose. I'm one of the MedTech analysts here at Canaccord. I covered the diabetes space. We're very excited to have with us DexCom this afternoon. DexCom is a leader in the glucose-monitoring segment of the diabetes space with what we view as really the best-in-class technology. So very excited to have with us Steve Pacelli, the Executive Vice President of Strategy and Corporate Development as well as Quentin Blackford, the CFO. There's a lot going on in diabetes. And I think it's a very compelling space. Valuations are -- if there's not a lot of volatility, valuation are stretched. But when I take a step back and I look at the underlying fundaments of the market, and they've never been stronger, both patient additions and then also your underlying technology. So I...

Transcript